GSK plc (GS71)

15.056
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    14.722 - 15.148
Trading near 52-week Low

GSK plc has hit the lowest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

GS71 Overview

Prev. Close
15.026
Day's Range
14.722-15.148
Revenue
38.43B
Open
15.05
52 wk Range
14.722-22.004
EPS
1.14
Volume
0
Market Cap
59.63B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
146,760
P/E Ratio
12.40
Beta
0.254
1-Year Change
-8.55%
Shares Outstanding
4,048,329,085
Next Earnings Date
-
What is your sentiment on GSK plc?
or
Vote to see community's results!

GSK plc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

GSK plc Analysis

GSK plc Company Profile

GSK plc Company Profile

Employees
90096
  • Type:Equity
  • Market:Germany
  • ISIN:GB0009252882
  • WKN:A3DMB5

GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. It has a global network of about 12 vaccines manufacturing sites.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuySellStrong SellStrong Sell
Technical IndicatorsBuyBuyStrong BuyStrong SellStrong Sell
SummaryBuyBuyNeutralStrong SellStrong Sell
  • target price 2290£ according to zone bourse
    0
    • 1st malaria vaccine approved by WHO. hopefully good news for the stock. definitely good for the developing world!
      1
      • Been In GSK since February and wearing almost a 15% gain which i'm pretty chuffed about , not sure what you guys think about GSK going into the future but i'm pretty happy with these returns and am thinking about investing in a PRE IPO called SpectrumX which i have seen on the homepage of LSE and the Sunday times. SpectrumXare leaders in proprietary formulations of HOCL, so looks promising for the future of pharmaceuticals. Have not dabbled with Pre IPOS so wanted to see what you guys think?
        2
        • to the moon!
          0
          • when?!
            0
          • Already mooned now buy back at 1300
            0
        • Good old GSK. Never fails to disappoint.
          0
          • AMAZING....great news, good earnings...it comes +2% to -0.7%....I`m done, I`m out
            0
          • As i said before this company does not understand competitive performance - radical change needed - one off hitting earnings forecast does not mean anything
            0
        • setting my buys at 12.5
          0
          • GSK will invent the vaccine of immortality
            0
            • Will not deliver on results - never does actually - the plans are all nice on paper - but its all just a financial excercise - the forecasts especially on oncology but not only are not real
              0
              • glx is about to split of the consumer division .
                0
                • Stock's been on fire these past 2 days. What's the driver?
                  0
                  • Anticipation that the briefing on the proposed split on 25 June will suggest an unlocking of value. GSK is a lame duck in the Covid race and in many other aspects, so also hope that the breakup will trigger bids for the separate businesses.
                    0